drugset / Trial / NCT03947138

A Study of GC3107(BCG Vaccine) in Healthy Infants

NCT03947138

Phase 3 Completed 750 enrolled Green Cross Corporation
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to investigate the efficacy and safety of GC3107 in healthy infants

Timeline

Start
2019-08-06
Primary completion
2022-06-20
Completion
2022-09-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator BCG SSI Vaccine 0.05 ml Other
Subject GC3107 Unknown 0.05 ml Other

Indications